The Impact Of Inclusion/Exclusion Criteria On Clinical Trial Diversity

By Kwame Marfo, Market Strategy and Innovation Lead, Clinical Development

In the past several years, the life sciences industry has evolved from having an awareness of the racial and ethnic imbalance in clinical trials to understanding its consequences. With recent data enhancements to Komodo’s Healthcare Map™ — including race and ethnicity (R&E) demographics for ~225 million patients — clinical development teams now have the tools needed to begin correcting the problem. The pragmatic question for many is: How, and where, do we begin to make improvements?

By examining how trial criteria affect patient participation, researchers can work to improve diversity and reduce bias in clinical trials. Discover how inclusive trial design can lead to better patient outcomes and more representative results.